Luveltamab tazevibulin,Pegfilgrastim
Sutro Biopharma,Amgen
['pivotal study', 'pivot,io,i', 'ovarian', '$stro', 'sutro']
$stro new article : sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal study reframe-o1 
Effortlessly track financial news and never miss an article again with https://t.co/hKE5DiO0B4. Our real-time database combines trusted financial news sources for easy access.